JOSÉ
HERNÁNDEZ QUERO
Investigador desde 2023
Hospital Universitario Príncipe de Asturias
Alcalá de Henares, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Príncipe de Asturias (11)
2022
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
2021
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study
HIV Medicine, Vol. 22, Núm. 9, pp. 867-876
-
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 73, Núm. 7, pp. e2026-e2033
2020
-
Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients
Journal of acquired immune deficiency syndromes (1999), Vol. 83, Núm. 3, pp. 292-300
2019
-
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
Scientific Reports, Vol. 9, Núm. 1
2018
-
Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status
Cells, Vol. 7, Núm. 11
-
Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
Open Forum Infectious Diseases, Vol. 5, Núm. 1
2017
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2008
-
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of hiv type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903
Clinical Infectious Diseases, Vol. 47, Núm. 8, pp. 1083-1092